Navigation Links
RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments
Date:1/13/2009

- After eight weeks of treatment, RAD001 halted tumor growth in 55% of advanced gastric cancer patients previously treated with chemotherapy

- Based on these promising data, Novartis will initiate a Phase III trial of RAD001 for advanced gastric cancer patients

- Gastric cancer is the second leading cause of cancer death worldwide with the majority of new cases occurring in East Asia

EAST HANOVER, N.J., Jan. 13 /PRNewswire/ -- Data released today show RAD001 (also known as everolimus; proposed brand name Afinitor(R)) halted tumor growth in 55% of patients with advanced gastric cancer, a condition for which there are limited treatment options. In addition, 45% of patients in the study demonstrated some tumor shrinkage(1).

The data will be presented at the American Society of Clinical Oncology's 2009 Gastrointestinal Cancers Symposium on January 15.

The open label, single arm, multi-center Phase II study of 54 patients conducted in Japan, is designed to assess the efficacy and safety of RAD001 in patients with advanced gastric cancer whose disease progressed despite prior treatment. Patients enrolled in the trial were heavily pre-treated. All trial participants were from Japan and of Asian descent (1).

"There are very limited treatment options for patients who progressed despite the standard treatment for this aggressive cancer," said Atsushi Ohtsu, MD, PhD, Director, Research Center for Innovative Oncology, National Cancer Center Hospital East, Chiba, Japan. "The results from this study demonstrate that RAD001 has the potential to provide an effective new option for these patients."

A global Phase III clinical trial program to evaluate the efficacy and safety of RAD001 monotherapy in approximately 500 advanced gastric cancer patients will begin enrollment this year.

"Most advanced gastric cancer patients eventually sto
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
2. RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
3. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
4. RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer
5. RAD001 Combined with Sandostatin LAR(R) Depot and as Monotherapy Controls Growth of Rare Pancreatic Neuroendocrine Tumors
6. Latest RAD001 Study Results Show Further Increase in Time Without Tumor Growth in Patients With Advanced Kidney Cancer
7. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
10. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 Nektar Therapeutics ... Inc. today announced positive results from its Phase ... investigational, extended half-life recombinant factor VIII (rFVIII) treatment ... (Recombinant)], which met its primary endpoint in reducing ... compared to the on-demand arm. Top-line ...
(Date:8/21/2014)... -- The spinal column is one of the most delicate ... and from the brain through the column control many key ... ailment here can be life altering, and leave the victim ... their body. Though back injury and disease can have an ... options available to make things better than ever before. ...
(Date:8/21/2014)... 21, 2014 /CNW/ - Eisai Limited is pleased to support ... first-of-its-kind comic book available in Canada . ... specifically to educate children and their parents about epilepsy, the ... affecting more than 300,000 Canadians. Eisai is guided by a ... in which the patient is central – there was a ...
Breaking Medicine Technology:Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... 5, 2011 Elekta,s MOSAIQ® Oncology Information System ... No. 1 ranking in the oncology software category from ... Category Leader designation identifies top-rated vendor products in the ... for each market segment. The 2010 ...
... (Nasdaq: BMRN ) today announced that Jean-Jacques Bienaime, ... at the J.P. Morgan 29th Annual Healthcare Conference in San ...   Interested parties may access a live audio ... the BioMarin website, www.BMRN.com .  A replay of the ...
Cached Medicine Technology:Elekta's MOSAIQ Oncology Information System Named Category Leader in '2010 Top 20 Best in KLAS Awards' Report 2Elekta's MOSAIQ Oncology Information System Named Category Leader in '2010 Top 20 Best in KLAS Awards' Report 3BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference 2
(Date:8/22/2014)... Beach, Florida (PRWEB) August 22, 2014 ... for Lasik in Fort Lauderdale at the most affordable ... get better eyesight through their advanced Lasik treatments. LASIK ... worldwide and the Braverman Eye Center has been delivering ... of patients live a glasses-free and contact lenses-free life ...
(Date:8/22/2014)... pain, breathing difficulties, fainting. Each year approx. 265,000 Danes ... serious illness. New research from Aarhus University and Aarhus ... as many as every fourth patient are sent ... symptoms that led to the acute hospitalisation., "Naturally, there ... at the hospital disprove that there is a serious ...
(Date:8/22/2014)... new study from Karolinska Institutet in Sweden provides insight ... touch, vision or sound from different sources and sides ... adequate movements. The findings, which are presented in the ... as a sensory ,hub, integrating various types of sensory ... types. , "The striatum is the main input structure ...
(Date:8/22/2014)... allergy is frequently confused with lactose intolerance. However, these ... body. People with lactose intolerance do not digest lactose ... In the case of the potentially much more dangerous ... milk proteins with its own IgE antibodies. , According ... in Europe suffer from a genuine milk allergy. Less ...
(Date:8/22/2014)... be able to better understand their risks of future ... with different treatments. , The findings, set out in ... are based on the experience of more than 2,000 ... cancer over a period of more than 40 years. ... lymphoma who receive certain types of chemotherapy or radiotherapy ...
Breaking Medicine News(10 mins):Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Many patients are discharged without a diagnosis 2Health News:The striatum acts as hub for multisensory integration 2Health News:Scientists uncover why major cow milk allergen is actually allergenic 2Health News:Scientists map risk of premature menopause after cancer treatment 2
... Support the Long Term Mental Health Needs ... SAN DIEGO, Oct. 24 As the hundreds of,thousands San ... what,happened and deal with the stress of the situation. These ... those directly and,indirectly affected. In the days, weeks and months ...
... Support The Cause In A Variety Of Ways ..., ... the,team,s First Annual Breast Cancer Awareness Night on Friday, October ... Joe Louis Arena. Doors open,at 6 p.m. for the 7:30 ... Hockey Fights Cancer month when all NHL players wore special ...
... MONTREAL, Oct. 24 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX ... to,announce a new two-phase strategy to have a ... for its lead product candidate, the,Hemaseel(R)HMN fibrin sealant, ... This "First-Patient-In" objective is a major milestone ...
... M. Foley, MD,of Memorial Sloan-Kettering Cancer Center in ... University of Utah School of Medicine, received the ... 2007 at the 9th,Annual Josefina Magno Conference on ... of palliative care, the science of pain and,symptom ...
... reduced toxicity, studies find, , , WEDNESDAY, Oct. 24 (HealthDay ... to the standard two-drug regimen used for head and ... reducing the toxicity, two new studies report. , The ... increased survival in both studies and more than doubled ...
... Norway October 24, 2007 - The use of ... increased incidence of reproductive endocrine disorders in both men ... the effects of withdrawal from two common AEDs, carbamazepine ... and female AED users. , The study finds ...
Cached Medicine News:Health News:San Diego Wildfires Mental Health Fund 2Health News:San Diego Wildfires Mental Health Fund 3Health News:Red Wings Host Breast Cancer Awareness Night 2Health News:Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials 2Health News:Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials 3Health News:Two Physicians Recognized for Work in Pain and Symptom Management 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 2Health News:Three Chemo Drugs Better Than Two for Advanced Head/Neck Cancers 3
... WatchMate system is designed to protect a ... and becoming lost or injured. Such residents ... etc., or have suffered a head injury., ... on their wrist or ankle, and points ...
... Smart™ Labels have a direct thermal ... Instruments Tag-it™ HF-I transponder. When processed ... text and other graphics may be ... data is programmed to the RFID ...
... a patent pending solution using Radio ... a smart label to promote patient ... wrong-site, wrong-procedure surgery. This simple to ... orthopedic surgeon with the operating room ...
... Hospitals, correctional facilities, recreational venues ... wristbands to provide automated data capture ... reducing costly and dangerous errors. RFID ... admissions wristbands at entertainment venues as ...
Medicine Products: